BlackSky Technology
Watchlist
TOP-5 Analyst Price Targets on April 10, 2025
Reading Time: 2 minutes
Verastem Inc. [US92337C2035]: Jefferies starts coverage with a Buy rating and price target of $15 (195% upside potential) The FDA has accepted the New Drug Application (NDA) for the combination of Avutometinib and Defactinib for the treatment of recurrent low-grade serous ovarian cancer (LGSOC) with KRAS mutation, granting priority review. The decision date (PDUFA date) is June 30, 2025. The treatment targets a rare form of ovarian cancer for which there are currently no approved therapies. Clinical data shows promising efficacy, particularly in...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
